Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 8/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.32 |
| ▸ | CFTR | P13569 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411236 | 0.80 | KMO (0.52) | KMOTRPA1 | |
| SCHEMBL16894281 | 0.80 | KMO (0.52) | KMOTRPA1 | |
| SCHEMBL893755 | 0.77 | KMO (0.56) | KMOCTSSDGAT1 | |
| SCHEMBL19795561 | 0.75 | KMO (0.50) | KMOGRM5CTSSUSP30DGAT1 | |
| SCHEMBL16635390 | 0.75 | AAK1 (0.39) | KMOTRPA1 | |
| SCHEMBL16635474 | 0.73 | KMO (0.55) | KMOCTSS | |
| SCHEMBL16635303 | 0.72 | KMO (0.54) | KMOTRPA1CYP1A2 | |
| SCHEMBL18223974 | 0.72 | KMO (0.43) | KMOGRM5CTSSDGAT1CYP1A2 | |
| SCHEMBL16635095 | 0.71 | TRPA1 (0.38) | TRPA1 | |
| SCHEMBL28074525 | 0.71 | CYP1A2 (0.52) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3101015-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180162844-A1 | CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3330266-A1 | CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3101015-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA Pharma Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| CN-105612153-A | Substituted sulfonamide compounds as TRPA1 conditioner | HOFFMANN LA ROCHE | 2016-05-25 | — | — | CN | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KMO 1510/4885GRM5 391/4885CTSS 2463/4885 |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KMO 1510/4885GRM5 391/4885CTSS 2463/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KMO 1510/4885GRM5 391/4885CTSS 2463/4885 |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | KMO 2240/4885GRM5 470/4885CTSS 1700/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KMO 1510/4885GRM5 391/4885CTSS 2463/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | KMO 2240/4885GRM5 470/4885CTSS 1700/4885 |
| US-20180162844-A1 | CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME | TRPA1, TRPV1, TRPV2 | KMO 2399/4885GRM5 335/4885CTSS 2205/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | KMO 1510/4885GRM5 391/4885CTSS 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.